JAN 18, 2021 7:00 AM PST

Arthritis Drug Approved for Critically Ill COVID Patients

WRITTEN BY: Tara Fernandes

Critically ill COVID patients in the U.K. may receive an arthritis drug after a study showed that treatment lowered mortality rates and accelerated recovery times in intensive care. 

The drug tocilizumab (Actemra) is an approved biologic medication for the treatment of rheumatoid arthritis. The drug works by blocking the inflammatory protein interleukin-6, or IL-6, to calm arthritis-induced joint swelling, pain, and other symptoms caused by inflammation. 

Researchers at the Imperial College London found that tocilizumab was also able to help COVID patients, reducing the mortality rate in critically ill individuals by around 10 percent and, on average, shortening their hospital stays by a week.

With the pandemic raging on in the new year, the list of existing treatments that have been tested to help COVID patients continues to grow. Unfortunately, except for the steroid treatment dexamethasone, few have been successful. 

Once the SARS-CoV-2 virus enters the body, infection typically manifests as influenza-like symptoms: cough, fever, and headaches. A subset of infected individuals spirals quickly into a state of potentially lethal hypoxemic respiratory failure—a condition caused by a massive surge of inflammatory factors in the body. These patients have markedly abnormal levels of IL-6, ferritin, and C-reactive proteins, among other molecules associated with the “cytokine storm.”

Tocilizumab’s life-saving effects are likely attributed to the drug’s ability to quench inflammation, specifically targeting IL-6. High circulating concentrations of this pro-inflammatory protein are associated with uncontrolled viral replication, a rapid decline in respiratory health, resulting in the need for mechanical ventilation, and even death. This led researchers to hypothesize that blocking IL-6 can help patients by halting the inflammatory cascade. 

The report from the REMAP-CAP trial indicates that the scientists may be on the right track. The ongoing clinical trial has enrolled nearly 4,000 patients in the U.K., with 350 of them receiving tocilizumab. Other pharmaceuticals targeting inflammation are also in the line-up for testing. 

 

Sources: The New England Journal of Medicine, Bloomberg.


 

About the Author
PhD
Interested in health technology and innovation.
You May Also Like
JUL 07, 2022
Clinical & Molecular DX
Single supplier for research and diagnostics workflows
JUL 07, 2022
Single supplier for research and diagnostics workflows
Enjoy the benefits of working with a single supplier for DNA isolation, protein purification, research, and diagnostics ...
JUL 01, 2022
Coronavirus
Nanobodies Could Protect Us From Every Variant
JUL 01, 2022
Nanobodies Could Protect Us From Every Variant
Immune reactive molecules called nanobodies, which are based on molecules found in llamas could offer robust protection ...
JUL 03, 2022
Neuroscience
Loss of Smell Reduces Enjoyment When Eating and Cooking
JUL 03, 2022
Loss of Smell Reduces Enjoyment When Eating and Cooking
Olfactory loss- or loss of smell- reduces enjoyment in eating and cooking. The corresponding study was published in Food ...
JUL 09, 2022
Drug Discovery & Development
Universal Vaccine for Influenza B Shows Promise
JUL 09, 2022
Universal Vaccine for Influenza B Shows Promise
A new universal flu vaccine has been shown to protect against influenza B viruses in cell and mouse models. The correspo ...
JUL 19, 2022
Immunology
A New Immune Trigger is Identified
JUL 19, 2022
A New Immune Trigger is Identified
The immune system relies on signals, which may be activated by the presence of a pathogen, for example. Chemokines are c ...
AUG 14, 2022
Immunology
After Transplant, Another Person is Cured of HIV
AUG 14, 2022
After Transplant, Another Person is Cured of HIV
For the second time this year and only the fourth time ever, researchers have announced that a person has been cured of ...
Loading Comments...